ReviewCureus2026
De-escalation of Axillary Surgery in Early-Stage Breast Cancer: A Comprehensive Narrative Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axillary management in early-stage breast cancer has shifted from routine axillary lymph node dissection (ALND) toward morbidity-sparing strategies that preserve oncologic outcomes. This narrative review summarizes the key practice-changing trials and contemporary guidance across the axillary de-escalation continuum: omission of completion ALND for limited sentinel lymph node metastasis, use of axillary radiotherapy when additional regional treatment is indicated, and omission of sentinel lymph node biopsy (SLNB) in carefully selected low-risk clinically node-negative patients. In the neoadjuvant setting, optimized SLNB and targeted axillary dissection can allow many initially node-positive patients to avoid ALND. Across scenarios, optimal axillary management increasingly depends on multidisciplinary integration of nodal burden, tumor biology, systemic therapy, and planned radiotherapy fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.